Journal of Substance Abuse Treatment 2007;32(2):167-175. [doi: 10.1016/j.jsat.2006.03.018]
Eric D. Collins, MD (Columbia University, LI Node), Terry Horton, MD (Phoenix House, LI Node), Katherine Reinke, RN (Phoenix House, LI Node), Leslie Amass, PhD (Friends Research Institute, PR Node), Edward V. Nunes, MD (Columbia University, LI Node).
Phoenix House, a Community Treatment Provider (CTP) in the Long Island Node, participated in the National Drug Abuse Treatment Clinical Trials Network (CTN) protocol NIDA-CTN-0001, "Buprenorphine/Naloxone versus Clonidine for Inpatient Opiate Detoxification." The resulting positive experience suggested to the medical and clinical staff at the CTP that a short-term on-site buprenorphine–naloxone regimen for medical withdrawal was safe and feasible, and held great promise as a tool to improve the early engagement and retention of opioid-dependent patients in long-term residential treatment. Phoenix House therefore established the "First Step" program for opioid-dependent patients entering the therapeutic community, in which an on-site, short-term, flexible regimen of buprenorphine–naloxone is provided and fully integrated into the initial phases of long-term residential treatment. This report describes the initial outcomes with this novel program, which is designed to utilize buprenorphine–naloxone as a bridge to ongoing participation in long-term residential treatment for opioid-dependent patients. (Article (Peer-Reviewed), PDF, English, 2007)
Keywords: Buprenorphine | Buprenorphine/Naloxone | CTN platform/ancillary study | Dissemination | Opioid dependence | Pharmacological therapy | Retention - Treatment | Suboxone |
Therapeutic community | Journal of Substance Abuse Treatment (journal)
Document No: 165, PMID: 17306725
Submitted by the CTN Dissemination Librarians, 1/29/2007.